Laurus Labs shares tumble nearly 9% after promoters sell stake worth Rs 500 crore; multibagger stock up 122% in one year
Laurus Labs shares fell nearly 9% after promoters, including founder and CEO Satyanarayana Chava, sold over 20 lakh shares worth Rs 487 crore. The stake sale followed a sharp rally that had taken the stock to a 52-week high.

Promoter selling triggers a sharp correction after Laurus Labs' record rally.
Laurus Labs shares plunged to Rs 2,211 apiece on NSE. The company’s founder and CEO Satyanarayana Chava sold more than 14.85 lakh shares worth more than Rs 360 crore at the previous closing price on November 11, the day the stock hit a 52-week high of Rs 2,488 apiece.
Several other promoters also joined the list of shareholders who pared some stake in the company on the day the stock hit a 52-week high. They included Senior Vice President of Business Development (Generics) N Babchand (15,000 shares), President of manufacturing and operations Srinivasa Rao S (10,000 shares), Suresh Kumar K (2,000 shares), Executive Vice President of Finance Chagarlamudi Sita Ramaiah (15,000 shares) and others.
Overall, promoters sold nearly 20.08 lakh shares worth nearly Rs 486.68 crore at the stock’s previous closing price of Rs 2,424 apiece.
Also read | Laurus Labs shifts gears as CDMO emerges as key growth driver; Nuvama sees 24% upside
Laurus Labs share price
This comes after a sharp uptrend in the multibagger stock, which has gained more than 128% in one year. After hitting a 52-week low of Rs 918 apiece in February this year, the stock rapidly rallied over 171% in nine months to hit a 52-week high of Rs 2,488 last week.
In the longer term, the stock has delivered skyrocketing returns of more than 492% in three years and 350% in five years. The company has a market capitalisation of more than Rs 1.22 lakh crore.
Laurus Labs Q2 Results
Laurus Labs, a research and development-driven pharmaceutical and biotechnology company, reported revenue of Rs 2,206 crore for Q2 FY27, compared with Rs 1,653 crore in the corresponding quarter last year.
Net profit surged 126% YoY to Rs 441 crore from Rs 195 crore in Q2 FY26, while EBITDA climbed 78% to Rs 762 crore against Rs 429 crore in the year-ago quarter. The company's EBITDA margin stood at 34.5% during the quarter, while gross margins expanded to 63%, compared with 59.9% in Q2FY26.
Commenting on the performance, Dr Satyanarayana Chava, Founder and Chief Executive Officer of Laurus Labs, said the company delivered another record quarter in terms of revenue and profitability, reflecting the strength of its CDMO platform and Affordable Medicines portfolio.
He highlighted the operationalisation of the company's first commercial-scale peptide manufacturing plant in Vizag, adding that a significant capacity expansion was already underway to address rising demand for peptide therapeutics. The company also announced targeted investments in oligonucleotides and peptide-resin technologies to strengthen its integrated CDMO capabilities.
Also read | Laurus Labs shares jump after Q2 results
Disclaimer: This article has been written by Debaroti Adhikary, who is not a SEBI-registered Research Analyst or an Investment Adviser. Debaroti Adhikary and his/her ‘relative(s)’ (as defined under Section 2(77) of the Companies Act, 2013) do not hold any financial interest in the companies mentioned in this article as of the date of publication. The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution. They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here.
Download ET Markets APP